Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER registry, 2010- to 2012

Clinical Breast Cancer

Volumn 15, Issue 1, 2015, Pages e27-e34

  Schroeder, Mary C ^a   Lynch, Charles F ^b   Abu Hejleh, Taher ^c   Chrischilles, Elizabeth A ^b   Thomas, Alexandra ^c  

^a UNIVERSITY OF IOWA   (United States)

^b Department of Epidemiology   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Antineoplastic agents; Breast neoplasms; Cancer registry; Mastectomy; Small tumor

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECEPTOR SUBTYPE; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MASTECTOMY; RECURRENCE RISK; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION; UNITED STATES; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLASSIFICATION; EPIDEMIOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; REGISTER; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IOWA; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; RETROSPECTIVE STUDIES; SEER PROGRAM;

EID: 84920278305     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.07.009     Document Type: Article

References (33)

1. R. Siegel, E. Ward, O. Brawley, and A. Jemal Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths Ca Cancer J Clin 61 2011 212 236
2. M. Schootman, D. Jeffe, A. Reschke, and R. Aft The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States Breast Cancer Res Treat 85 2004 219 222
3. T. Kennedy, A.K. Stewart, K.Y. Bilimoria, L. Patel-Parekh, S.F. Sener, and D.P. Winchester Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients Ann Surg Oncol 14 2007 2918 2927
4. C. Luke, A.M. Nguyen, K. Priest, and D. Roder Female breast cancers are getting smaller, but socio-demographic differences remain Aust N Z J Public Health 28 2004 312 316
5. J. Fracheboud, S.J. Otto, and J.A. van Dijck Decreased rates of advanced breast cancer due to mammography screening in The Netherlands Br J Cancer 91 2004 861 867
6. P.M. Vacek, B.M. Geller, D.L. Weaver, and R.S. Foster Jr. Increased mammography use and its impact on earlier breast cancer detection in Vermont, 1975-1999 Cancer 94 2002 2160 2168
7. L.G. Arnesson, S. Smeds, and G. Fagerberg Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening The Eur J Surg 160 1994 271 276
8. A.K. Lee, M. Loda, and G. Mackarem Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome Cancer 79 1997 761 771
9. S.P. Leitner, A.S. Swern, D. Weinberger, L.J. Duncan, and R.V. Hutter Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0) Cancer 76 1995 2266 2274
10. P.P. Rosen, S. Groshen, D.W. Kinne, and L. Norton Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up J Clin Oncol 11 1993 2090 2100
11. E.O. Hanrahan, A.M. Gonzalez-Angulo, and S.H. Giordano Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma J Clin Oncol 25 2007 4952 4960
12. E.R. Fisher, J.P. Costantino, and M.E. Leon Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21 Cancer 110 2007 1929 1936
13. G. Cancello, P. Maisonneuve, and N. Rotmensz Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes Breast Cancer Res Treat 127 2011 713 720
14. P. Sanpaolo, V. Barbieri, D. Genovesi, V. Fusco, and G. Ausili Cefaro Biologically effective dose and breast cancer conservative treatment: is duration of radiation therapy really important? Breast Cancer Res Treat 134 2012 81 87
15. L. Livi, I. Meattini, and C. Saieva Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer Cancer 118 2012 3236 3243
16. R.L. Theriault, J.K. Litton, and E.A. Mittendorf Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype Clin Breast Cancer 11 2011 325 331
17. Y.H. Park, S.T. Kim, and E.Y. Cho A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 119 2010 653 661
18. A.M. Gonzalez-Angulo, J.K. Litton, and K.R. Broglio High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller J Clin Oncol 27 2009 5700 5706
19. F. Petrelli, and S. Barni Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis Med Oncol 29 2012 2586 2593
20. J.H. Kwon, Y.J. Kim, and K.W. Lee Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less BMC Cancer 10 2010 557
21. A.Y. Ho, G. Gupta, and T.A. King Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy Cancer 118 2012 4944 4952
22. L. Adepoju, S. Wanjiku, and M. Brown Effect of insurance payer status on the surgical treatment of early stage breast cancer: data analysis from a single health system JAMA Surg 148 2013 570 572
23. E.B. Habermann, A. Abbott, H.M. Parsons, B.A. Virnig, W.B. Al-Refaie, and T.M. Tuttle Are mastectomy rates really increasing in the United States? J Clin Oncol 28 2010 3437 3441
24. Surveillance Epidemiology, and End Results Program. SEER coding and staging manuals. Available at: http://www.seer.cancer.gov/tools/codingmanuals/index.html. Accessed: November, 12, 2013.
25. A. Fritz, C. Percy, and A. Jack International Classification of Diseases for Oncology Third ed 2000 World Health Organization Geneva
26. T. Gamucci, A. Vaccaro, and F. Ciancola Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis Journal of cancer research and clinical oncology 139 May 2013 853 860
27. S. Amar, A.E. McCullough, and W. Tan Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status Oncologist 15 2010 1043 1049
28. G. Curigliano, G. Viale, and V. Bagnardi Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer J Clin Oncol 27 2009 5693 5699
29. A. Goldhirsch, W.C. Wood, and A.S. Coates Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 2011 1736 1747
30. I.M. Vaz Duarte Luis, R.A. Ottesen, and M.E. Hughes Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in women with T1N0 breast cancer (BC) in the National Comprehensive Cancer Network (NCCN) J Clin Oncol 31 15 suppl 2013 abstract 1006
31. U. Mahmood, A.L. Hanlon, and M. Koshy Increasing national mastectomy rates for the treatment of early stage breast cancer Ann Surg Oncol 20 2013 1436 1443
32. J.L. Warren, and L.C. Harlan Can cancer registry data be used to study cancer treatment? Med Care 41 2003 1003 1005
33. J.L. Malin, K.L. Kahn, J. Adams, L. Kwan, M. Laouri, and P.A. Ganz Validity of cancer registry data for measuring the quality of breast cancer care J Natl Cancer Inst 94 2002 835 844